SecBot SecBot

CRBP

Corbus Pharmaceuticals Holdings, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001595097 Biotech & Drug Discovery
$3.99 −0.06 (−1.48%)
Oct 26 4:00 PM ET · prev $4.05
Market cap
$79.9M
Micro cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$35.00
+777% · range $28.00–48.00
Next earnings
Nov 10
in 15 days · EPS est. −$1.21
1 year
−76.5%
from $17.01 · Oct 27
30 days
−42.3%
from $6.92
52-week range
$3.99–17.12
at the low
Avg volume 20D
854.1K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$278.5K
1 buyer · 5 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/7 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation. The presentation…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $126.3K at an average $7.84. 5 insiders sold $404.8K. Price is 49% below their cost.

  • InstitutionsMIXED

    Q2 2026: 17 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.034 → −$1.214 over 90 days. 2 up, 7 down in 30 days.

  • TrendDOWNTREND

    48% below its 50-day average. New closing low $3.99 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,331,135$12.5M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED423,374$4.0M
STATE STREET CORPDOUBLED254,672$2.4M
DIMENSIONAL FUND ADVISORS LPADD190,214$1.8M
JANE STREET GROUP, LLCADD139,133$1.3M
NORTHERN TRUST CORPDOUBLED124,906$1.2M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED111,302$1.0M
RENAISSANCE TECHNOLOGIES LLCTRIM110,822$1.0M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy7Buy8Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +777%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 14, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 7, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Aug 7, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 23, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Jun 17, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 27, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$126.3K
bought · 1 insider
$404.8K
sold · 5 insiders
−49.1%
vs their $7.84 cost
DateInsiderTypeValue
Sep 14, 2026
Ben Yong
Director
SELL$15.7K
Aug 16, 2026
Nicacio Leonardo Viana
Chief Medical Officer
AWARD58,333 sh
Aug 16, 2026
Nicacio Leonardo Viana
Chief Medical Officer
AWARD191,676 sh
Aug 11, 2026
Saxena Nishant C
Chief Business Officer
BUY$25.0K
Aug 7, 2026
Moran Sean F.
Chief Financial Officer
SELL$121.0K
Aug 7, 2026
Cohen Yuval
Chief Executive Officer
SELL$171.4K
Jun 3, 2026
Saxena Nishant C
Chief Business Officer
BUY$68.2K
Jun 2, 2026
Saxena Nishant C
Chief Business Officer
BUY$33.0K

Earnings setup

Estimates
Nov 10
reports in 15 days
−$1.21
EPS estimate, this quarter
−17%
estimate change, 90 days
2↑ 7↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.21-$1.91–-$0.73+0.0%$1.1M
Next Q-$1.32-$1.74–-$0.74+0.0%$0.00
Current FY-$5.43-$6.81–-$4.06+0.0%$1.1M
Next FY-$5.51-$6.90–-$2.97+0.0%$2.4M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation. The presentation highlights Phase…
8-K — Impact 5/10
Sep 30, 2026 SEC
RA Capital Management, L.P. and affiliated entities filed a Schedule 13G disclosing a 9.9% passive stake in Corbus…
SC 13G — Impact 4/10
Sep 22, 2026 SEC
Institutional activity in CRBP during Q2 2026 was mixed: 17 buyers added $5.4M in new positions (led by passive index…
INST-CLUSTER — Impact 3/10
Sep 15, 2026 Short interest report
Short Interest: CRBP up 23% to 2.8M shares
Settlement 2026-09-15 | Days to cover: 1.54 | ≈14.27% of shares outstanding (est.)
Sep 14, 2026 Insider
Ben Yong sold 2,000 shares
Director @ $7.84 ($15.7K)
Sep 11, 2026 Press
Corbus Pharmaceuticals announced a conference call for September 14 to discuss topline Phase 1b data for CRB-913, its…
Impact 5/10
Aug 16, 2026 Insider
Nicacio Leonardo Viana was granted 58,333 shares
Chief Medical Officer
Aug 16, 2026 Insider
Nicacio Leonardo Viana was granted 191,676 shares
Chief Medical Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
CRBP Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 15, 2026
Short interest
Short Interest: CRBP up 23% to 2.8M shares
Settlement 2026-09-15 | Days to cover: 1.54 | ≈14.27% of shares outstanding (est.)
Sep 11, 2026
FDA
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT
Aug 17, 2026
Press release
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new…
Aug 6, 2026
Earnings
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
NORWOOD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage…
Aug 3, 2026
Earnings date
CRBP Q2 2026 Earnings Scheduled — 2026-08-03

SecBot reports

17 filings · 2 press releases · 3 bullish · 1 bearish · 3 mixed · 10 neutral
All CRBP filing & press-release reports (19)